Key Points
- Elanco CEO Jeffrey Simmons bought 22,000 shares on Dec. 11 at an average price of $21.75 for $478,500, increasing his direct stake to 167,000 shares (a 15.17% rise) as disclosed in an SEC Form 4.
- Elanco beat quarterly EPS estimates ($0.19 vs. $0.13) with revenue up 10.4% year-over-year and set FY2025 guidance of $0.91–$0.94 EPS and Q4 guidance of $0.09–$0.12.
- Analyst sentiment is broadly positive with a MarketBeat consensus of "Moderate Buy" and a $22.78 target, while several firms (Barclays, UBS, KeyCorp) have issued overweight/buy ratings and higher price targets (up to $30).
Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) insider Rajeev Modi acquired 4,500 shares of the company's stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the acquisition, the insider owned 123,082 shares of the company's stock, valued at $2,625,339.06. The trade was a 3.79% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Elanco Animal Health Stock Up 2.0%
Shares of ELAN stock opened at $21.72 on Tuesday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $23.70. The stock has a market cap of $10.79 billion, a P/E ratio of 361.98, a P/E/G ratio of 2.89 and a beta of 1.86. The company has a 50 day simple moving average of $21.75 and a two-hundred day simple moving average of $18.16.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion for the quarter, compared to analysts' expectations of $1.09 billion. During the same quarter last year, the company posted $0.13 EPS. The company's revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.
Institutional Investors Weigh In On Elanco Animal Health
A number of institutional investors have recently added to or reduced their stakes in ELAN. UBS Group AG lifted its holdings in shares of Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock worth $331,669,000 after buying an additional 5,961,457 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after purchasing an additional 2,563,740 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Elanco Animal Health by 322.0% during the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company's stock valued at $46,192,000 after purchasing an additional 2,468,122 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Finally, Bowen Hanes & Co. Inc. purchased a new position in shares of Elanco Animal Health during the third quarter valued at about $47,626,000. 97.48% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. Barclays started coverage on Elanco Animal Health in a research report on Tuesday, December 9th. They issued an "overweight" rating and a $30.00 price target for the company. Stifel Nicolaus boosted their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. KeyCorp restated an "overweight" rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Zacks Research downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. raised shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.78.
Get Our Latest Research Report on Elanco Animal Health
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
